Thrombocytopenia is a prevalent blood abnormality, especially in elderly patients or those with cancer [1], and could increase the risk of anticoagulation-associated bleeding. However, there is a scarcity of evidence for optimal management strategies for anticoagulation therapy in patients with venous thromboembolism (VTE) complicated with thrombocytopenia. Currently, direct oral anticoagulant (DOAC) for VTE has been widely used in routine clinical practice [2]. The effect of baseline thrombocytopenia on clinical outcomes in patients with VTE in the DOAC era remains unclear.
